Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01173497 | A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis | PHASE2 | COMPLETED | 44 | — | — | Jul 1, 2010 | Jul 1, 2013 | Mar 17, 2016 | 13 | United States |
AS measured by intra or extra cranial time to progression (TTP)
| Arm | Type | Description |
|---|---|---|
| INIPARIB, irinotecan | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| INIPARIB + irinotecan | DRUG | 21 day cycle |
Inclusion Criteria - 1. Histologically-confirmed, ER negative, PR negative and Her2 negative adenocarcinoma of the breast with brain lesion on radiographic imaging. 2. ECOG Performance Status of 0-2. 3. Life expectancy of \>12 weeks. 4. No limit to prior therapies with last anti-cancer treatment ≥ ...